-
n this issue: Stop smoking drug Chantix rates stronger warning from FDA; Type 2 diabetes surgery on the way?; Vytorin study inconclusive; Influenza A virus found resistant to Tamiflu; FDA actions.
-
-
-
Most critically ill patients require mechanical ventilation, and, according to one large survey, the weaning process occupies about 40% of the time that patients spend connected to the ventilator.
-
-
A chronic inflammatory disease that affects the central nervous system, multiple sclerosis (MS) is one of the leading causes of neurologic disability in young and middle-aged adults.
-
FDA cleared for marketing BD Diagnostics' GeneOhm StaphSR assay that uses molecular methods to determine whether a blood sample contains Staphylococcus aureus bacterium. It's the first rapid blood test for the drug-resistant MRSA (methicillin-resistant Staphylococcus aureus), which can cause deadly infections.
-
The California Department of Public Health says Los Angeles' Cedars-Sinai Medical Center's handling of high-risk drugs placed its pediatric patients in harms way.
-
Electronic drug interaction alerts can be useful in preventing harmful drug-drug interactions, but too many clinically insignificant alerts can lead to "alert fatigue" and clinically significant alerts may be overridden.
-
FDA recently announced these approvals: Biogen Idec's Tysabri® (natalizumab) has been approved by FDA for treating moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional Crohn's disease therapies.
